Business Wire

Enterprise AI Hits the Wall: NTT DATA Research Reveals Growing Privacy and Sovereignty Barriers

14.5.2026 14:00:00 CEST | Business Wire | Press Release

Share

NTT DATA, a global leader in AI, digital business and technology services, today released new research showing that enterprise AI is outgrowing the architecture and infrastructure beneath it as data privacy and sovereignty requirements tighten. The research finds a widening split between enterprises that are redesigning AI for control, locality and security, and organizations still layering AI into environments that were not built to support these requirements.

For years, enterprise architecture moved data across systems, clouds, applications and borders with increasing speed and efficiency. AI is exposing the limits of that model. Sensitive data must be protected, workloads must run inside defined jurisdictions, and models must be governed under tighter controls. Data cannot always move with the speed and fluidity many AI systems expect, making jurisdiction a core architectural constraint. As a result, private and sovereign AI have become critical considerations.

NTT DATA’s 2026 Global AI Report: A Playbook for Private and Sovereign AI reveals a gap between what organizations know they need and what they are ready to build:

  • More than 95% of respondents say private and sovereign AI are important, but only 29% are prioritizing sovereign AI in a concrete, near-term way.
  • About 35% of CAIOs identify building, integrating and managing complex AI models in private or sovereign environments as their top barrier to adoption, and nearly 60% of AI leaders cite cross-border data restrictions as a major challenge.
  • Only 38% report high confidence in their cloud security posture—a critical foundation for both private and sovereign AI.

Private and sovereign AI are related, but distinct. Private AI focuses on protecting sensitive enterprise data, controlling access and limiting exposure. Sovereign AI focuses on ensuring that AI systems, data and operating environments meet jurisdictional, regulatory or national and regional control requirements.

"As AI evolves, private and sovereign approaches are testing enterprise readiness," said Abhijit Dubey, CEO and Chief AI Officer, NTT DATA, Inc. "The organizations that are succeeding are going beyond regulatory compliance and risk mitigation. They are building the operating foundation for AI that can perform across markets, jurisdictions and business environments. Our research shows AI leaders are pulling ahead by treating architecture, infrastructure and governance as strategic requirements."

The report identifies five shifts defining the next phase of enterprise AI:

  1. AI is running into a wall – and it’s not the model. The constraint is no longer model performance alone. AI now requires greater control over compute, data access, security and locality—exposing the limits of infrastructure built for centralized, borderless data flows.
  2. Data jurisdiction is now an architectural constraint. Data can still move, just not the way AI needs. Because AI depends on continuous access and movement of data, jurisdiction is shaping where data lives, where models run and how systems are designed and governed.
  3. Everyone sees the shift—few are acting on it. More than 95% of organizations recognize the importance of private and sovereign AI, but only around one-third are prioritizing sovereign AI in a concrete, near-term way.
  4. Leaders are redesigning early and moving decisively—creating competitive divergence. Leaders are moving decisively, aligning infrastructure, governance and operating models early. This is enabling them to move faster from pilots to scaled deployments, while others struggle to adapt.
  5. Private and sovereign AI sounds like independence—in practice, they rely on tightly orchestrated ecosystems. More than half of organizations cite integration complexity as their top challenge. As organizations push for greater control, they are also increasing the complexity and interdependence of their AI ecosystem partners coordinating across the stack.

Together, private and sovereign AI are changing how AI systems are built, governed and scaled. Organizations that redesign early are better positioned in regulated, distributed and data-sensitive environments. Those that layer AI into architectures that were not built for control, locality or data-flow constraints may struggle to turn their AI ambition into durable value.

The report draws on two studies engaging a total of nearly 5,000 senior decision-makers across more than a dozen industries, more than 30 markets and five regions. It is part of NTT DATA's global research series on strategies that separate AI leaders from the market.

About NTT DATA

NTT DATA is a $30+ billion business and technology services leader, serving 75% of the Fortune Global 100. We are committed to accelerating client success and positively impacting society through responsible innovation. We are one of the world’s leading AI and digital infrastructure providers, with unmatched capabilities in enterprise-scale AI, cloud, security, connectivity, data centers and application services. Our consulting and industry solutions help organizations and society move confidently and sustainably into the digital future. As a Global Top Employer, we have experts in more than 70 countries. We also offer clients access to a robust ecosystem of innovation centers as well as established and start-up partners. NTT DATA is part of NTT Group, which invests over $3 billion each year in R&D.

Visit us at nttdata.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20260514228841/en/

Contacts

NTT DATA, Inc.
Dan.Smith@nttdata.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press Release

Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press Release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press Release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press Release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press Release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye